Wegovy (semaglutide 2.4 mg) is a prescription medicine licensed in the UK for weight management in adults with obesity (BMI 30 kg/m) or overweight (BMI 27 kg/m) with at least one weight-related comorbidity, such as type 2 diabetes, hypertension, or obstructive sleep apnoea
Tirzepatide not only aids in shedding pounds, but also contributes significantly towards stabilizing blood sugar levelsthis benefit is particularly crucial for individuals grappling with type 2 diabetes
Who is typically covered by insurance for Wegovy
But it is not a solution it does not burn fat and it will not help people who have a lot of weight to lose
, an endocrinologist and diabetes and metabolism specialist at Duke Health, "Within three to six months, I'm looking to see a decrease in their hemoglobin A1C and to see a more stable pattern of blood glucose overall, she says